UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

AMICUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-33497		20-0422823
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
6 Cedar Brook Drive, Cranbury, NJ				08512
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000
(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 2.02. Results of Operations and Financial Condition.

     On August 7, 2007, Amicus Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2007. A copy of this press release is attached hereto as Exhibit 99.1.

     In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(c)

Exhibits.

99.1

— Press Release, dated August 7, 2007

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AMICUS THERAPEUTICS, INC.
Date: August 7, 2007		By:		/s/ DOUGLAS A. BRANCH
		Name:		Douglas A. Branch
		Title:		Vice President, General Counsel and Secretary

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated August 7, 2007

Exhibit 99.1

Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Cranbury, NJ, August 2, 2007 — Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the second quarter of 2007. On a reported basis, calculated in accordance with U.S. generally accepted accounting principals (GAAP), Amicus announced a net loss attributable to common stockholders per share of $1.37 for the three months ended June 30, 2007. On a non-GAAP basis, Amicus reported a net loss attributable to common stockholders per share of $1.17 for the three months ended June 30, 2007. As of June 30, 2007, cash, cash equivalents, and marketable securities totaled $125.7 million.

“We continue to remain very confident in the potential for pharmacological chaperones to treat a range of human genetic diseases, beginning with the lysosomal storage disorders,” stated John F. Crowley, President and CEO of Amicus Therapeutics. “We expect to deliver on three significant clinical milestones by the end of 2007: Phase II data for Amigal™ for Fabry disease; preliminary Phase II data in the 4-week Plicera™ switching study; and, complete Phase I data for AT2220 for Pompe disease.”

Quarterly Highlights:

•

Amicus completed its IPO and sold a total of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds to Amicus totaled $75.0 million and after underwriting discounts and commissions and offering expenses, net proceeds totaled $68.1 million.

Financial Results

On a reported basis, the net loss attributable to common stockholders for the three months ended June 30, 2007 was $9.7 million as compared to $28.1 million for the same period in 2006. On a Non-GAAP basis, the net loss for the three months ended June 30, 2007 and the three months ended June 30, 2006 was $8.3 million, respectively. The Company recorded no revenues during these periods.

On a Non-GAAP basis, research and development expense for the three months ended June 30, 2007, was $6.4 million, an increase of $0.1 million from $6.3 million for the three months ended June 30, 2006.

On a Non-GAAP basis, general and administrative expense for the three months ended June 30, 2007, was $2.6 million, an increase of $0.4 million from $2.2 million from the three months ended June 30, 2006.

The differences between U.S. GAAP EPS, net loss, research and development and general and administrative and the corresponding non-GAAP amounts are itemized in table 2, and are due to:

•		Pre-tax share-based compensation expense under SFAS 123R of $1.0 million (or $0.14 per share), primarily related to employee stock option expense.
•		Pre-tax charge for a deemed dividend of $19.4 million in the second quarter of 2006.
•		Pre-tax charges for preferred stock accretion.

•

Pre-tax charges for changes in the fair value of warrant liability.

Use of Non-GAAP Financial Measures

Our “non-GAAP net income” and “non-GAAP diluted EPS” financial measures are defined as reported, or GAAP, net income and diluted EPS excluding, for the reasons discussed below, (1) stock option expense and the cumulative effect of an accounting change relating to the initial adoption of SFAS No. 123R and (2) other items. Our management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of the Company from year to year and quarter to quarter. Accordingly, we believe investors’ understanding of the Company’s financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net income and diluted EPS should not be viewed in isolation or as a substitute for reported, or GAAP, net income and diluted EPS.

(1)		Stock option expense — Non-GAAP net income and diluted EPS exclude the impact of our stock option expense recorded in accordance with SFAS No. 123R. We believe that excluding the impact of expensing stock options better reflects the recurring economic characteristics of our business.
(2)		Other items — Non-GAAP net income and diluted EPS exclude other unusual or non-recurring items that are evaluated on an individual basis. Our evaluation of whether to exclude an item for purposes of determining our non-GAAP financial measures considers both the quantitative and qualitative aspects of the item, including, among other things (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. Items excluded for purposes of determining non-GAAP net income and diluted EPS include deemed dividends, preferred stock accretion, and changes in the fair value of warrant liability.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal™ for the treatment of Fabry disease and Plicera™ for the treatment of Gaucher disease. The Company is also conducting Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are “forward-looking statements” within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “should,” and “could,” and similar expressions or

words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the respective Phase II clinical trials for Amigal™ and Plicera™, and the Phase I clinical trial for AT2220 may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Contact:
Investors, Jim Dentzer or Corporate, Matthew Patterson, both of Amicus Therapeutics, +1-609-662-2000, or Media, Dan Budwick of BMC Communications Group for Amicus Therapeutics, +1-212-477-9007, ext. 14

Table 1

Amicus Therapeutics, Inc.
(a development stage company)

Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)

																		Period
																		from
																		February
																		4,
																		2002
		Three Months								Six Months								(inception)
		Ended June 30,								Ended June 30,								to June 30,
		2006				2007				2006				2007				2007
Operating Expenses:
Research and development		$	6,691			$	6,783			$	12,719			$	13,867			$	72,671
General and administrative			2,563				3,189				4,464				6,040				28,832
Impairment of leasehold Improvements			—				—				—				—				1,030
Depreciation and amortization			217				312				416				609				2,166
In-process research and Development			—				—				—				—				418
Total operating expenses			9,471				10,284				17,599				20,516				105,117
Loss from operations			(9,471	)			(10,284	)			(17,599	)			(20,516	)			(105,117	)
Other income (expenses):
Interest income			448				1,060				686				1,753				4,560
Interest expense			(74	)			(86	)			(125	)			(179	)			(1,261	)
Change in fair value of warrant Liability			471				(86	)			127				(149	)			(454	)
Other expense			2				—				(1	)			—				(1,181	)
Loss before tax benefit			(8,624	)			(9,396	)			(16,912	)			(19,091	)			(103,453	)
Income tax benefit			—				—				—				—				695
Net loss			(8,624	)			(9,396	)			(16,912	)			(19,091	)			(102,758	)
Deemed dividend			(19,424	)			—				(19,424	)			—				(19,424	)
Preferred stock accretion			(41	)			(310	)			(81	)			(351	)			(802	)
Net loss attributable to common stockholders		$	(28,089	)		$	(9,706	)		$	(36,417	)		$	(19,442	)		$	(122,984	)
Net loss attributable to common stockholders per common share — basic and diluted		$	(39.04	)		$	(1.37	)		$	(57.78	)		$	(4.80	)
Weighted-average common shares outstanding — basic and diluted			719,556				7,083,748				630,230				4,051,709

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc
Statement of Operations Information for 3 months
ending June 30, 2007

						Change in Fair
						Value of				Preferred
						Warrant				Stock				Stock				GAAP as
		Non-GAAP				Liability				Accretion				Compensation				Reported
Income Statement Classifications:
Research and development			(6,361	)											(422	)			(6,783	)
General and administrative			(2,607	)											(582	)			(3,189	)
Depreciation and amortization			(312	)															(312	)
Interest income			1,060																1,060
Interest expense			(86	)															(86	)
Change in fair value of warrant liability			—				(86	)											(86	)
Preferred stock accretion			—								(310	)							(310	)
Summary:
Income (loss) before income taxes:			(8,306	)			(86	)			(310	)			(1,004	)			(9,706	)
Net income (loss):			(8,307	)			(86	)			(310	)			(1,004	)			(9,707	)
Net income (loss) per share — basic and diluted:			(1.17	)			(0.01	)			(0.04	)			(0.14	)			(1.37	)
Weighted average number of shares outstanding:			7,083,748																7,083,748

Table 2

Amicus Therapeutics, Inc
Statement of Operations Information for 3 months
ending June 30, 2006

						Change in
						Fair Value				Preferred
						of Warrant				Stock				Deemed				Stock				GAAP as
		Non-GAAP				Liability				Accretion				Dividend				Compensation				Reported
Income Statement Classifications:
Research and development			(6,295	)															(396	)			(6,691	)
General and administrative			(2,202	)															(361	)			(2,563	)
Depreciation and amortization			(217	)																			(217	)
Interest income			448																				448
Interest expense			(73	)																			(73	)
Change in fair value of warrant liability			(0	)			471																471
Other			2																				2
Deemed dividend			—												(19,424	)							(19,424	)
Preferred stock accretion			—								(41	)											(41	)
Summary:
Income (loss) before income taxes:			(8,338	)			471				(41	)			(19,424	)			(757	)			(28,089	)
Net income (loss):			(8,338	)			471				(41	)			(19,424	)			(757	)			(28,089	)
Net income (loss) per share — basic and diluted:			(11.59	)			0.65				(0.06	)			(26.99	)			(1.05	)			(39.04	)
Weighted average number of shares outstanding:			719,556																				719,556